Residency · Residency · Ophthalmology

Ocular Surface Squamous Neoplasia and Conjunctival Melanoma

Introduction

Ocular surface squamous neoplasia (OSSN) and conjunctival melanoma are the two most important malignancies of the conjunctival and corneal epithelium. OSSN encompasses a spectrum from dysplasia to carcinoma in situ to invasive squamous cell carcinoma. Conjunctival melanoma, though rare, carries significant risk of recurrence, regional lymph node metastasis, and mortality. Early recognition and appropriate management are essential.

Ocular Surface Squamous Neoplasia (OSSN)

Epidemiology

Most common malignancy of the ocular surface. Incidence: 0.02-3.5 per 100,000; highest near the equator. Risk factors: ultraviolet light exposure, advanced age, male sex, fair skin. Human papillomavirus (HPV) types 16 and 18: associated in some populations. HIV/AIDS: significantly increased risk; presents at younger age with more aggressive behavior. Xeroderma pigmentosum: markedly increased risk.

Clinical Features

Typically arises at the limbus (interpalpebral zone, nasal or temporal) Appearance: gelatinous, papillomatous, or leukoplakic mass. Conjunctival intraepithelial neoplasia (CIN): flat, vascular, gelatinous lesion. Invasive SCC: nodular, more elevated, may invade the cornea or sclera. Feeder vessels and intrinsic vascularity common. Corneal involvement: grey, opalescent epithelial change with a sharp leading edge.

Rarely invades intraocularly or into the orbit (advanced cases)

Diagnosis

Incisional or excisional biopsy with histopathological confirmation. Impression cytology: non-invasive adjunct for diagnosis and margin assessment. Anterior segment OCT (AS-OCT): hyperreflective, thickened epithelium with an abrupt transition zone; useful for monitoring treatment response. UBM for suspected scleral or intraocular invasion.

Histopathologic Classification

Mild dysplasia: atypical cells in lower third of epithelium. Moderate dysplasia: atypical cells in lower two-thirds. Severe dysplasia / CIS: full-thickness dysplasia without basement membrane breach. Invasive SCC: penetration through the basement membrane into substantia propria. Mucoepidermoid and spindle cell variants carry worse prognosis.

Management

Surgical Excision

"No-touch" technique with alcohol-assisted epitheliectomy for corneal component. Wide excision with 3-4 mm conjunctival margins. Cryotherapy to conjunctival edges (double freeze-thaw technique) Absolute alcohol to corneal surface to remove residual epithelial cells. Amniotic membrane transplant for large defects. Map biopsy of margins or intraoperative frozen section if available.

Topical Chemotherapy

Interferon alpha-2b (IFN-a2b): 1 million IU/mL topical drops, 4 times daily for 2-3 months. Well tolerated; minimal side effects (flu-like symptoms with high doses) Can be used as primary therapy, adjuvant, or neoadjuvant. Complete resolution in 80-90% of cases as primary therapy. 5-Fluorouracil (5-FU): 1% topical, 4 times daily for 1 week on / 1 week off (4 cycles) Effective but more toxic to the ocular surface.

Mitomycin C (MMC): 0.02-0.04% topical, 4 times daily for 1 week on / 1 week off (3-4 cycles) Potent but significant epitheliotoxicity; reserved for refractory or extensive cases. Topical chemotherapy is increasingly used as primary treatment for diffuse or multifocal OSSN.

Recurrence and Follow-Up

Recurrence rate: 5-30% depending on margin status and treatment modality. Follow-up every 3-4 months for 2 years, then biannually. AS-OCT is valuable for non-invasive monitoring of treatment response and early recurrence detection.

Conjunctival Melanoma

Epidemiology

Rare: incidence approximately 0.2-0.5 per million per year. Almost exclusively in Caucasians; median age 55-65 years. Accounts for 1-2% of all ocular melanomas but has higher per-tumor mortality than uveal melanoma in early stages.

Origin and Precursor Lesions

Primary acquired melanosis (PAM) with atypia: most important precursor; 50-75% of conjunctival melanomas arise from PAM. Conjunctival nevus: transformation is uncommon (< 1%) De novo: no identifiable precursor lesion (approximately 20-30%)

PAM Classification

PAM without atypia: benign; low risk of melanoma (0-3%) PAM with atypia: significant risk of melanoma (13-46% depending on degree of atypia) Mild, moderate, or severe atypia based on cytologic and architectural features. Pagetoid spread and epithelioid cell morphology carry highest risk.

Clinical Features

Pigmented nodular mass on the conjunctiva; may be amelanotic (20%) Associated flat, patchy melanosis (PAM) in surrounding conjunctiva. Feeder and intrinsic vessels; may be highly vascular. Most common location: bulbar conjunctiva, especially limbal/perilimbal area. Can involve fornix, palpebral conjunctiva, caruncle, plica. Forniceal and palpebral involvement carries worse prognosis.

Diagnosis and Workup

Excisional biopsy with wide margins (3-4 mm) and cryotherapy to wound edges. Map biopsies of surrounding flat pigmented areas to evaluate for PAM with atypia. Histopathology: melanocytic proliferation invading substantia propria; assess depth (Breslow-like thickness) Immunohistochemistry: S-100, HMB-45, Melan-A, SOX-10. Sentinel lymph node biopsy for tumors > 2 mm thickness or non-limbal location. Systemic staging: PET/CT, brain MRI for advanced or recurrent disease.

Molecular: BRAF, NRAS, KIT mutations (different profile from uveal melanoma)

Management

Surgical

Wide local excision with 3-4 mm margins. Cryotherapy to wound edges (double freeze-thaw) Alcohol-assisted corneal epitheliectomy if limbal involvement. Lamellar or full-thickness scleral resection if scleral invasion. Exenteration: reserved for extensive orbital invasion (rare with modern approach)

Adjuvant Therapies

Topical mitomycin C (0.04%): adjuvant for PAM with atypia and melanoma. Topical interferon alpha-2b: for PAM with atypia. Plaque brachytherapy: for focal recurrence or residual disease. Proton beam radiation: for extensive or recurrent disease. Systemic therapy for metastatic disease: immune checkpoint inhibitors (pembrolizumab, nivolumab) and BRAF/MEK inhibitors (if BRAF-mutant)

Prognosis

10-year mortality: 25-30%. Local recurrence: 40-60% (higher with positive margins, PAM with atypia) Regional metastasis: preauricular and submandibular lymph nodes (most common) Distant metastasis: lung, liver, brain, bone. Poor prognostic factors: non-limbal location, tumor thickness > 2 mm, positive margins, ulceration, pagetoid invasion.

Key Clinical Pearls

OSSN typically arises at the limbus in the interpalpebral zone; topical interferon alpha-2b is increasingly used as primary therapy with high success rates. Primary acquired melanosis with atypia is the most common precursor to conjunctival melanoma and requires excision with map biopsies and cryotherapy. Unlike uveal melanoma, conjunctival melanoma harbors BRAF mutations and may respond to targeted therapy and immune checkpoint inhibitors. Anterior segment OCT is a valuable non-invasive tool for monitoring OSSN treatment response.

References

1. Shields CL, Chien JL, Surakiatchanukul T, et al. Conjunctival tumors: review of clinical features, risks, biomarkers, and outcomes. Indian J Ophthalmol. 2019;67(12):1930-1946.
2. Nanji AA, Sayyad FE, Galor A, et al. High-resolution optical coherence tomography as an adjunctive tool in the diagnosis of corneal and conjunctival pathology. Ocul Surf. 2015;13(3):226-235.
3. Shields CL, Markowitz JS, Belinsky I, et al. Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases. Ophthalmology. 2011;118(2):389-395.
4. Galor A, Karp CL, Oellers P, et al. Predictors of ocular surface squamous neoplasia recurrence after excisional surgery. Ophthalmology. 2012;119(10):1974-1981.

Read this lecture as Markdown